- Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, leveraging its proprietary Alector Brain Carrier platform to enhance drug delivery across the blood-brain barrier.
- In the past year, Alector has filed a $400 million mixed shelf registration and received upgrades from analysts, including a recent upgrade to 'Overweight' from Cantor Fitzgerald on April 15, 2026.
- The company is advancing multiple clinical programs, including AL137 for Alzheimer's Disease and AL050 for Parkinson's Disease, with significant partnerships in the biotech sector to enhance its research capabilities.
- Alector's ideal buyers are pharmaceutical companies and healthcare providers focused on neurodegenerative diseases, as their therapies aim to address critical unmet needs in treating conditions like Alzheimer's and Parkinson's, making them a compelling target for sales engagement.
Engineering is the largest function with 70 employees (about 34% of the company). Healthcare has 29 employees (~14%), and Business Management has 25 (~12%). Operations (19; ~9%), Finance and Administration (16; ~8%), and Human Resources (13; ~6%) follow. Smaller groups include Sales and Support (8), Risk, Safety, and Compliance (6), and Legal (5), with 15 employees categorized as Other.
San Francisco, CA is the largest single location with 83 employees (about 40% of total headcount). Additional Bay Area locations include South San Francisco (22), San Mateo (7), San Jose (5), and Redwood City (3), together representing roughly 58% of the workforce. Other U.S. hubs include San Diego (7), Los Angeles (3), Philadelphia (3), and Seattle (2). A distributed “Other” category accounts for 71 employees across additional locations.
